▼ SELL
$ Value
$32.7M
Shares
2,854,607
Price
$11
Filed
Jun 27
Insider
Name
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Title
—
CIK
0001615258
Roles
10% Owner
Transaction Details
Transaction Date
2025-06-27
Code
S
Table
Non-Derivative
Ownership
Indirect
Equity Swap
No
Shares After
—
Footnotes
The shares were sold pursuant to that certain Underwriting Agreement. dated June 25, 2025, among Fosun Pharma USA Inc., the Issuer, and the underwriter party thereto. | Fosun Pharma USA Inc. is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | Fosun Industrial Co., Limited is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Filing Info
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2025-06-27 | NATR | ▼ | $32.7M |
Other Insiders at NATR (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Yates Bryant J
EVP & President, Europe
|
— | $475K | 2026-04-20 |
|
Brower Nathan G
EVP, General Counsel
|
— | — | 2026-04-20 |
|
Romanzi Kenneth G.
Chief Executive Officer
|
— | — | 2026-03-06 |
|
Fritz Erich A
EVP, Global Supply Chain
|
— | — | 2026-03-06 |
|
Norman Daniel C
EVP & President, Asia
|
— | $377K | 2026-04-20 |
|
Lanoy Jonathan David
SVP, Chief Accounting Officer
|
— | $99K | 2026-04-20 |
|
Jones Leslie Shane
EVP & Chief Financial Officer
|
— | — | 2026-04-20 |
|
Herbert Kevin R.
EVP & President, North America
|
— | — | 2026-03-11 |
|
Fuller Kevin Gregory
Global Chief Marketing Officer
|
— | — | 2026-03-10 |